Log In
BCIQ
Print this Print this
 

GZ402663, sFLT-01

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionAnti-VEGF chimeric molecules delivered by AAV vectors
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$65.0M

$20.0M

$45.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/06/2013

$65.0M

$20.0M

$45.0M

Get a free BioCentury trial today